Practical, step-by-step guides for anyone starting or managing GLP-1 treatment. Learn how to begin safely, what to expect week by week, and how to get the most from your medication with confidence.
Patient Guides
Some people taking GLP-1 medications like semaglutide or tirzepatide report an unusual change in their breath. This article explains why it happens, whether it signals something worth discussing with your doctor, and what you can do about it today.
Medicare is moving toward covering GLP-1 medications for weight management, a shift that could affect millions of older adults. Here is what weight management experts want patients to understand about eligibility, costs, and what this coverage actually includes.
Medicare coverage for GLP-1 medications like semaglutide and tirzepatide is expanding, creating new opportunities for older adults managing obesity or related conditions. This guide breaks down what's actually covered, what you'll likely still pay out of pocket, and how to navigate the system without overpaying.
A recent study suggests newer diabetes and weight loss drugs, including GLP-1 agonists, may be associated with certain autoimmune risks. Here is what the research actually says, what it means for patients considering or currently taking these medications, and the right questions to bring to your doctor.
Generic versions of Ozempic (semaglutide) are generating significant buzz, but the reality of when and how they'll reach patients is more complicated than headlines suggest. This article breaks down what a generic actually means, the current legal and regulatory landscape, and what your practical options are right now if cost is a barrier.
Mounjaro (tirzepatide) is increasingly prescribed to adults over 50, but age brings specific considerations around muscle loss, blood pressure, and drug interactions. This guide covers what older adults need to know before starting, including practical questions to bring to your doctor and cost-saving options.
A rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy has been linked to Wegovy in emerging research. This article breaks down what the condition is, how significant the risk appears to be, and what current and prospective patients should discuss with their doctors.
Emerging research suggests that GLP-1 medications like semaglutide (Wegovy) may do more than promote weight loss - they could also reduce the joint inflammation that drives arthritis. For people managing both obesity and arthritis, this potential dual benefit is worth understanding. Here is what the science currently shows and what questions to bring to your doctor.
.avif)
.avif)